NEW

RADLogics’ AI-Powered Applications Available on Nuance AI Marketplace

RADLogics recently announced that its AI-Powered medical imaging applications designed to assist in the detection and quantification of findings associated with COVID-19 will be available on the Nuance AI Marketplace. The Nuance AI Marketplace is a portal with...

AHRA Announces Election Results

AHRA’s online Board of Directors election closed at midnight on May 18, 2020. The newest members of the AHRA Board of Directors are: 2020-2021 President-Elect: Kimlyn Queen-Weis, CRA, FAHRA Kimlyn joined AHRA in 2004, earned her CRA in 2004, and achieved Fellow...

United Imaging Wins Multiple Stevie Awards

United Imaging was named the winner of five Stevie Awards in the 18th Annual American Business Awards, including a Gold Award for “Most Innovative Company of the Year – Up to 2,500 Employees” for its U.S.-based operations, which were established in 2018. United...

Life Image Launches Patient Connect Portal

Life Image, a global medical evidence network specializing in curating diagnostic images for care delivery and research, has announced the launch of its Patient Connect Portal. The platform gives patients control over their own images and medical data to help manage...

Varian Acquires CyberHeart

Varian has acquired CyberHeart, a privately-held company with intellectual property (IP) that covers the use of radiation in the heart (cardiac radioablation) and other forms of radiosurgery for cardiovascular disease.

“Based on the early positive clinical results in ventricular tachycardia we have seen from other investigators, we believe that this technology can offer hope to cardiac arrhythmia patients,” said Dee Khuntia, chief medical officer at Varian. “Cardiac radioablation would truly be a paradigm shift, bringing together two specialties – radiation oncology and cardiac electrophysiology – to collaborate in the treatment of cardiac patients.”

“Varian has a long track record of innovations in the field of radiation medicine and has successfully commercialized radiosurgery technology for treating both benign and malignant lesions,” said Kolleen Kennedy, president of Varian Proton Solutions and chief growth officer. “We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space.”

First in-human studies of radioablation in the treatment of cardiac arrhythmias have been published in the New England Journal of Medicine and Circulation.

“While cardiac radioablation technologies are not yet approved by the FDA, we feel that the results of these recent early studies are promising enough to warrant investment in this area,” Kennedy said.  “We’re now working to evaluate the CyberHeart IP portfolio and determine priorities for development and clinical trials going forward.”

Varian’s acquisition of CyberHeart involved the transfer of IP.

Acquisition Highlights:

  • The CyberHeart acquisition secures significant intellectual property/patents that cover the use of radiation in the heart.
  • Early positive clinical evidence suggests that cardiac radioablation has the potential to offer hope to patients with intractable cardiac arrhythmias.
  • Acquisitions are a critical step in Varian’s long-term strategy to become a global leader in multi-disciplinary, integrated cancer solutions as well as other applications of radiation medicine.

For more information, visit www.varian.com.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *